Effective Delivery of Dietary Probiotics
Lead Participant:
EMINATE LIMITED
Abstract
This project aims to address the probiotic market and problems with making claims on their efficacy. Currently EFSA has rejected any health claims to be made on probiotics sold in Europe. One of the main reasons for this being a lack of demonstrable cause and effect data.
The probiotic dietary supplementation is a £15Bn global industry, the one overriding challenge that has not been solved is the development of a rapid, in-vivo (in body) assay for proving the efficacy of probiotic delivery in the gut. This means that there is a real need to develop a quick test which can show if, and how well, a probiotic is acting in the gut. This project aims to produce a commercialisable probiotic delivery system for optimal gut health, with proven efficacy.
The probiotic dietary supplementation is a £15Bn global industry, the one overriding challenge that has not been solved is the development of a rapid, in-vivo (in body) assay for proving the efficacy of probiotic delivery in the gut. This means that there is a real need to develop a quick test which can show if, and how well, a probiotic is acting in the gut. This project aims to produce a commercialisable probiotic delivery system for optimal gut health, with proven efficacy.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| EMINATE LIMITED | £137,397 | £ 9,603 |
Participant |
||
| UNIVERSITY OF NOTTINGHAM | £148,828 | £ 148,828 |
| POLYMER SYSTEMS TECHNOLOGY LIMITED | £14,706 | £ 7,000 |
| FLAVOMETRIX LIMITED | £21,621 | £ 8,648 |
| WREN LABORATORIES LIMITED | £33,799 | £ 4,097 |
People |
ORCID iD |